Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA..
BACKGROUND: The optimal range of serum iron markers and usefulness of iron supplementation are uncertain in patients with pre-dialysis chronic kidney disease (CKD). We investigated the association between serum iron indices and risk of cardiovascular disease (CVD) events and the effectiveness of iron supplementation using Chronic Kidney Disease Japan Cohort data.
METHODS: We included 1416 patients ages 20-75 years with pre-dialysis CKD. The tested exposures were serum transferrin saturation and serum ferritin levels and the outcome measures were any cardiovascular event. Fine-Gray subdistribution hazard models were used to examine the association between serum iron indices and time to events. The multivariable fractional polynomial interaction approach was used to evaluate whether serum iron indices were effect modifiers of the association between iron supplementation and cardiovascular events.
RESULTS: The overall incidence rate of CVD events for a median of 4.12 years was 26.7 events/1000 person-years. Patients with serum transferrin saturation <20% demonstrated an increased risk of CVD [subdistribution hazard ratio (HR) 2.13] and congestive heart failure (subdistribution HR 2.42). The magnitude of reduction in CVD risk with iron supplementation was greater in patients with lower transferrin saturations (P = .042).
CONCLUSIONS: Maintaining transferrin saturation >20% and adequate iron supplementation may effectively reduce the risk of CVD events in patients with pre-dialysis CKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 38(2023), 12 vom: 30. Nov., Seite 2713-2722 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hasegawa, Takeshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 05.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ndt/gfad096 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357047508 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357047508 | ||
| 003 | DE-627 | ||
| 005 | 20231226071742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ndt/gfad096 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357047508 | ||
| 035 | |a (NLM)37202214 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hasegawa, Takeshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 05.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. | ||
| 520 | |a BACKGROUND: The optimal range of serum iron markers and usefulness of iron supplementation are uncertain in patients with pre-dialysis chronic kidney disease (CKD). We investigated the association between serum iron indices and risk of cardiovascular disease (CVD) events and the effectiveness of iron supplementation using Chronic Kidney Disease Japan Cohort data | ||
| 520 | |a METHODS: We included 1416 patients ages 20-75 years with pre-dialysis CKD. The tested exposures were serum transferrin saturation and serum ferritin levels and the outcome measures were any cardiovascular event. Fine-Gray subdistribution hazard models were used to examine the association between serum iron indices and time to events. The multivariable fractional polynomial interaction approach was used to evaluate whether serum iron indices were effect modifiers of the association between iron supplementation and cardiovascular events | ||
| 520 | |a RESULTS: The overall incidence rate of CVD events for a median of 4.12 years was 26.7 events/1000 person-years. Patients with serum transferrin saturation <20% demonstrated an increased risk of CVD [subdistribution hazard ratio (HR) 2.13] and congestive heart failure (subdistribution HR 2.42). The magnitude of reduction in CVD risk with iron supplementation was greater in patients with lower transferrin saturations (P = .042) | ||
| 520 | |a CONCLUSIONS: Maintaining transferrin saturation >20% and adequate iron supplementation may effectively reduce the risk of CVD events in patients with pre-dialysis CKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CKD | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a iron deficiency | |
| 650 | 4 | |a iron supplementation | |
| 650 | 4 | |a pre-dialysis | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Transferrins |2 NLM | |
| 700 | 1 | |a Imaizumi, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hamano, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Murotani, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Naohiko |e verfasserin |4 aut | |
| 700 | 1 | |a Komaba, Hirotaka |e verfasserin |4 aut | |
| 700 | 1 | |a Ando, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Shoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nangaku, Masaomi |e verfasserin |4 aut | |
| 700 | 1 | |a Nitta, Kosaku |e verfasserin |4 aut | |
| 700 | 1 | |a Hirakata, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Isaka, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Fukagawa, Masafumi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |d 1990 |g 38(2023), 12 vom: 30. Nov., Seite 2713-2722 |w (DE-627)NLM012639206 |x 1460-2385 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:12 |g day:30 |g month:11 |g pages:2713-2722 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ndt/gfad096 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 12 |b 30 |c 11 |h 2713-2722 | ||